|
May 9
|
Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
|
|
May 7
|
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
|
May 1
|
Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum
|
|
Apr 24
|
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting
|
|
Apr 19
|
These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?
|
|
Apr 12
|
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024
|
|
Apr 2
|
Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
|
|
Mar 12
|
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
|
|
Mar 6
|
Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit
|
|
Feb 28
|
Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer
|
|
Jan 9
|
Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)
|
|
Dec 18
|
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU
|
|
Dec 1
|
Is Corbus Pharmaceuticals (CRBP) Stock Outpacing Its Medical Peers This Year?
|
|
Oct 3
|
Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert’ Series (Session 2) on CRB-701 on October 10, 2023
|
|
Sep 27
|
Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on its Anti-aVb8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting
|